- Lyell Immunopharma (NASDAQ:LYEL) registers 625,000 common shares for resale by selling stockholders.
- Shares were issued as additional merger consideration under the October 2024 merger agreement with ImmPACT Bio.
- Issuance triggered by achievement of a clinical milestone tied to ImmPACT Bio’s next-gen CAR T-cell product.
- Milestone was met, and shares issued to stockholders on July 2, 2025.
- Lyell will not receive any proceeds from the resale.
